Palatin Provides Update on Anticipated 2025 Corporate Milestones
Press Releases
January 28, 2025

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Obesity programs:Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideTopline results expected 1Q calendar year 2025General obesity, weight loss management, and rare neuroendocrine and genetic

bradford

The Bradford Era

More by this Author
Local & Social